Proventil hfa 90 mg
Pro Research Analysisby 
Searched over 200M research papers
Proventil HFA 90 mg: Efficacy, Safety, and Comparisons
Efficacy of Proventil HFA in Bronchodilation
Bronchodilator Effectiveness Compared to Ventolin
Proventil HFA, a reformulated albuterol using hydrofluoroalkane (HFA) as a propellant, has been shown to provide bronchodilation comparable to Ventolin over a 12-week period. In a randomized, double-blind, placebo-controlled study, both Proventil HFA and Ventolin demonstrated similar efficacy in improving forced expiratory volume in 1 second (FEV1) across multiple time points (weeks 0, 4, 8, and 12)2. This study confirmed that Proventil HFA is as effective as Ventolin in managing asthma symptoms over an extended period.
Protection Against Methacholine-Induced Bronchoconstriction
A study comparing the relative potency of Proventil HFA and Ventolin-CFC in protecting against methacholine-induced bronchoconstriction found that Proventil HFA is bioequivalent to Ventolin-CFC. The protective effects were measured using doses of 100, 200, and 400 micrograms, and the results indicated no significant difference in efficacy between the two formulations1. This supports the use of Proventil HFA as an effective alternative to Ventolin-CFC.
Safety Profile of Proventil HFA
Comparable Safety to Ventolin
In terms of safety, Proventil HFA has a profile similar to that of Ventolin. Over a 12-week period, adverse event rates were comparable between the two treatments. Both medications were well-tolerated, with no significant changes in heart rate, blood pressure, or laboratory test results3. This indicates that Proventil HFA is a safe option for long-term use in asthmatic patients.
Safety in Preventing Exercise-Induced Bronchoconstriction
Proventil HFA has also been shown to be effective and safe in preventing exercise-induced bronchoconstriction (EIB) in children. In a study involving asthmatic children aged 6-11, Proventil HFA provided protection against EIB comparable to albuterol formulated in chlorofluorocarbons (CFCs) and significantly better than placebo. The safety profile, including heart rate and blood pressure changes, was similar across all active treatments4. This makes Proventil HFA a reliable option for managing EIB in pediatric patients.
Conclusion
Proventil HFA is an effective and safe bronchodilator for managing asthma symptoms and preventing exercise-induced bronchoconstriction. Its efficacy is comparable to Ventolin, and it has a similar safety profile, making it a suitable alternative for patients requiring long-term asthma management. The transition from CFC to HFA propellants in Proventil HFA does not compromise its effectiveness or safety, ensuring continued protection and relief for asthmatic patients1 2 3 4 5.
Sources and full results
Most relevant research papers on this topic
Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist.
Proventil-HFA salbutamol is bioequivalent to Ventolin-CFC salbutamol, with 100- and 200-microgram doses being sufficient for bronchoprotection against methacholine bronchoconstriction.
RCTProventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics.
Proventil HFA provides bronchodilation comparable to Ventolin and superior to HFA-134a placebo over 12 weeks of regular dosing, but response diminishes after 4 weeks.
RCT
Large Human TrialProventil HFA and ventolin have similar safety profiles during regular use.
Proventil HFA and Ventolin have similar safety profiles during regular use, with both not causing asthma control to deteriorate during regular use.
RCTProventil HFA prevents exercise-induced bronchoconstriction in children.
HFA albuterol is as effective as CFC-formulated albuterol and more effective than placebo in protecting asthmatic children from exercise-induced bronchoconstriction.
RCTProventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin.
Proventil HFA provides comparable protection against exercise-induced bronchoconstriction to Ventolin and Proventil, with a safer profile compared to placebo.
RCTThe effect of a holding chamber on albuterol metered-dose inhaler product differences.
Ventolin, Proventil, and ProAir are not interchangeable products, with Proventil or ProAir providing 2 to 3 times the dose of albuterol sulfate likely to reach the lungs compared to Ventolin, requiring 3 additional puffs for similar clinical benefit.
Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.
Salbutamol pMDI with HFA-134a formulation shows lower oral deposition but higher lung deposition, with spacers in Proventil HFA reducing oropharyngeal deposition and increasing lung deposition.
Highly CitedQuantification of Aerosol Hydrofluoroalkane HFA‐134a Elimination in the Exhaled Human Breath Following Inhaled Corticosteroids Administration
Breath HFA-134a levels can be used to assess inhaler medication compliance and evaluate the effectiveness of asthma medication delivery.
RCT
Rigorous JournalComparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
The HFA Modulite inhaler, CFC and DPI inhalers, and dry powder inhalers all provide significant improvements in bronchoprotection compared to placebo, with no significant difference in bronchodilator effects.
RCTThe Effect of a Holding Chamber on Albuterol Metered-Dose Inhaler Product Differences
A valved holding chamber may impact drug delivery and reduce systemic adverse effects in albuterol metered-dose inhaler products.
Non-RCT